CombiGene AB (publ) (COMBI.ST)
SEK 2.38
(-2.46%)
SEK 2.38
(-2.46%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.15 Million SEK | -31.85% |
| 2022 | 6.09 Million SEK | -23.21% |
| 2021 | 7.94 Million SEK | -0.49% |
| 2020 | 7.98 Million SEK | -66.06% |
| 2019 | 23.51 Million SEK | 60.38% |
| 2018 | 14.66 Million SEK | 801.06% |
| 2017 | 1.62 Million SEK | 100.96% |
| 2016 | 809.66 Thousand SEK | 17.05% |
| 2015 | 691.73 Thousand SEK | 18.85% |
| 2014 | 582.04 Thousand SEK | 1320.21% |
| 2013 | 40.98 Thousand SEK | -86.18% |
| 2012 | 296.57 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 5.95 Million SEK | -4.17% |
| 2024 Q1 | 6.21 Million SEK | 49.57% |
| 2023 Q3 | 5.43 Million SEK | -15.38% |
| 2023 Q2 | 6.41 Million SEK | 10.18% |
| 2023 Q4 | 4.15 Million SEK | -23.48% |
| 2023 FY | 4.15 Million SEK | -31.85% |
| 2023 Q1 | 5.82 Million SEK | -4.49% |
| 2022 Q2 | 5.38 Million SEK | -22.58% |
| 2022 Q3 | 6.13 Million SEK | 13.88% |
| 2022 Q4 | 6.09 Million SEK | -0.61% |
| 2022 FY | 6.09 Million SEK | -23.21% |
| 2022 Q1 | 6.95 Million SEK | -12.38% |
| 2021 FY | 7.94 Million SEK | -0.49% |
| 2021 Q4 | 7.94 Million SEK | 63.38% |
| 2021 Q3 | 4.86 Million SEK | 21.31% |
| 2021 Q2 | 4 Million SEK | -52.1% |
| 2021 Q1 | 8.36 Million SEK | 4.83% |
| 2020 FY | 7.98 Million SEK | -66.06% |
| 2020 Q3 | 11.54 Million SEK | -14.54% |
| 2020 Q2 | 13.51 Million SEK | -47.4% |
| 2020 Q4 | 7.98 Million SEK | -30.88% |
| 2020 Q1 | 25.69 Million SEK | 9.26% |
| 2019 Q4 | 23.51 Million SEK | 367.84% |
| 2019 FY | 23.51 Million SEK | 60.38% |
| 2019 Q2 | 10.45 Million SEK | -18.11% |
| 2019 Q3 | 5.02 Million SEK | -51.9% |
| 2019 Q1 | 12.76 Million SEK | -12.96% |
| 2018 Q1 | 1.17 Million SEK | -27.85% |
| 2018 Q2 | 1.3 Million SEK | 11.07% |
| 2018 Q4 | 14.66 Million SEK | -47.52% |
| 2018 FY | 14.66 Million SEK | 801.06% |
| 2018 Q3 | 27.93 Million SEK | 2042.18% |
| 2017 Q1 | 1.3 Million SEK | 60.81% |
| 2017 Q3 | 1.51 Million SEK | 124.37% |
| 2017 Q4 | 1.62 Million SEK | 7.11% |
| 2017 FY | 1.62 Million SEK | 100.96% |
| 2017 Q2 | 677 Thousand SEK | -48.0% |
| 2016 FY | 809.66 Thousand SEK | 17.05% |
| 2016 Q3 | 1.22 Million SEK | 39.54% |
| 2016 Q1 | 801 Thousand SEK | 15.54% |
| 2016 Q4 | 809.66 Thousand SEK | -33.69% |
| 2016 Q2 | 875 Thousand SEK | 9.24% |
| 2015 Q4 | 693.29 Thousand SEK | 188.87% |
| 2015 Q2 | 425 Thousand SEK | -36.19% |
| 2015 Q1 | 666 Thousand SEK | 14.42% |
| 2015 FY | 691.73 Thousand SEK | 18.85% |
| 2015 Q3 | 240 Thousand SEK | -43.53% |
| 2014 Q4 | 582.04 Thousand SEK | 0.0% |
| 2014 FY | 582.04 Thousand SEK | 1320.21% |
| 2014 Q1 | - SEK | 0.0% |
| 2013 FY | 40.98 Thousand SEK | -86.18% |
| 2012 FY | 296.57 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.735% |
| AcouSort AB (publ) | 10.37 Million SEK | 59.954% |
| Active Biotech AB (publ) | 13.4 Million SEK | 68.985% |
| Alzinova AB (publ) | 9.33 Million SEK | 55.46% |
| Amniotics AB (publ) | 10.54 Million SEK | 60.595% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | 6.1% |
| BioArctic AB (publ) | 139.5 Million SEK | 97.021% |
| Camurus AB (publ) | 414.81 Million SEK | 98.998% |
| Cantargia AB (publ) | 54.97 Million SEK | 92.44% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -8.286% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 69.822% |
| Genovis AB (publ.) | 98.04 Million SEK | 95.761% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 77.528% |
| Mendus AB (publ) | 51.22 Million SEK | 91.887% |
| Kancera AB (publ) | 17.97 Million SEK | 76.883% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 64.076% |
| LIDDS AB (publ) | 3.75 Million SEK | -10.65% |
| Lipum AB (publ) | 7.53 Million SEK | 44.866% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | 19.426% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 96.648% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -76.176% |
| NextCell Pharma AB | 13.68 Million SEK | 69.64% |
| OncoZenge AB (publ) | 1.69 Million SEK | -144.614% |
| Saniona AB (publ) | 86.08 Million SEK | 95.172% |
| Simris Alg AB (publ) | 148.93 Million SEK | 97.21% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 89.828% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 99.138% |
| Xintela AB (publ) | 14.01 Million SEK | 70.346% |
| Ziccum AB (publ) | 6.38 Million SEK | 34.941% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 78.314% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 94.216% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 94.156% |
| Intervacc AB (publ) | 21.68 Million SEK | 80.83% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 96.101% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 87.989% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 84.439% |
| Corline Biomedical AB | 6.78 Million SEK | 38.783% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 93.227% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 74.214% |
| Aptahem AB (publ) | 8.99 Million SEK | 53.811% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 91.0% |
| Fluicell AB (publ) | 8.91 Million SEK | 53.382% |
| Biovica International AB (publ) | 34.76 Million SEK | 88.046% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 64.381% |
| Abliva AB (publ) | 16.78 Million SEK | 75.234% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 98.063% |
| 2cureX AB (publ) | 2.93 Million SEK | -41.601% |
| I-Tech AB | 16.2 Million SEK | 74.354% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.65% |
| Cyxone AB (publ) | 4.69 Million SEK | 11.461% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 68.818% |
| Biosergen AB | 5.08 Million SEK | 18.269% |
| Nanologica AB (publ) | 79.32 Million SEK | 94.761% |
| SynAct Pharma AB | 51.83 Million SEK | 91.982% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 47.717% |
| BioInvent International AB (publ) | 90.45 Million SEK | 95.405% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | 19.999% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 97.711% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -131.661% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 67.389% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 42.755% |